Methods for treating diseases caused by deficiencies of recombinant alpha-L-iduronidase

A method of treating a human disease caused all or in part by a deficiency in α-L-iduronidase, comprising administering to a subject presenting the symptoms of said disease a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified human recombinant α-L-iduronidase of SEQ ID NO:2, or a biologically active fragment of SEQ ID NO:2 which possesses the same or similar biological activity of a human recombinant α-L-iduronidase of SEQ ID NO:2, wherein said human recombinant α-L-iduronidase of SEQ ID NO:2, or biologically active fragment thereof in said pharmaceutical composition has a purity of about 99% or greater, in an amount effective to alleviate the symptoms of said deficiency in α-L-iduronidase.

A method of treating a human disease caused all or in part by a deficiency in α-L-iduronidase, comprising administering to a human subject in need thereof a pharmaceutical composition comprising a purified human recombinant α-L-iduronidase of SEQ ID NO:2 and a pharmaceutically acceptable carrier, wherein said human recombinant α-L-iduronidase of SEQ ID NO:2 has a purity of about 99% or greater.

A method of treating human diseases caused all or in part by a deficiency in α-L-iduronidase, comprising the steps of:

• (a) administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified human recombinant α-L-iduronidase of SEQ ID NO:2, or biologically active fragment of SEQ ID NO:2 which possesses the same or similar biological activity to SEQ ID NO:2, wherein said human recombinant α-L-iduronidase of SEQ ID NO:2, biologically active fragment thereof has a purity of greater than about 99%, to a human subject in need thereof;
• and
• (b) optimizing said treatment by evaluating biochemical and clinical symptoms of said subject through routine assessment of history, physical examination, echocardiography, electrocardiography, magnetic resonance imaging, polysomnography, skeletal survey, range of motion measurements, corneal photographs, or skin biopsy.

A method of treating diseases caused all or in part by a deficiency in α-L-iduronidase, comprising the steps of:

• administering a pharmaceutical composition to a human subject in need thereof;
• wherein said pharmaceutical composition comprises a purified human recombinant α-L-iduronidase of SEQ ID NO:2, or biologically active fragment of SEQ ID NO:2 which possesses the same or similar biological activity to SEQ ID NO:2 wherein said human recombinant α-L-iduronidase of SEQ ID NO:2, or biologically active fragment has a purity of greater than about 99%.